Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice
Nutrients · 28.08.2023 · 15 (17) · 3765
DOI: 10.3390/nu15173765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 28.08.2023. Verfasst von Yermek Rakhat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Integrative Physiology, Kansai Electric Power Medical Research Institute, Kyoto 604-8436, Japan. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Eating, Diet, High-Fat, Mice, Obese. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Kieikai Research Foundation, Japan Association for Diabetes Education and Care (JADEC).
Abstract (Originalsprache)
The first oral form of the glucagon-like peptide-1 receptor agonist, oral semaglutide, has recently been launched and potently controls glycemia and body weight in subjects with type 2 diabetes. This drug carries the absorption enhancer and requires specific protocols of administration. The mechanism of action of oral semaglutide is not fully understood, for which an appropriate experimental model is required. This study explores the metabolic effects of oral semaglutide in mice under human protocols and doses. Oral semaglutide was bolus and once daily injected into high-fat diet-induced obese (DIO) mice under human protocols, followed by monitoring blood glucose, food intake, and body weight. Oral semaglutide 0.23 mg/kg, a comparable human dose (14 mg) in a small volume of water under human protocols rapidly decreased blood glucose and food intake and continuously reduced food intake and weight gain for 3 days in DIO mice. At 0.7 mg/kg (42 mg), this drug was somewhat more potent. Oral semaglutide with human protocols and doses rapidly reduces blood glucose and food intake and continuously suppresses feeding and weight in DIO mice. This study establishes mice as a model suitable for analyzing the mechanism of anti-obesity/diabetes actions of oral semaglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Integrative Physiology, Kansai Electric Power Medical Research Institute, Kyoto 604-8436, Japan.
- Department of Diabetes, Endocrinology and Metabolism/Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
- Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka 553-0003, Japan.
- Center for One Medicine Innovative Translational Research, Gifu University Institute for Advanced Study, Gifu 501-1193, Japan.
ORCID-Profile: Yermek Rakhat, Daisuke Yabe
Förderung
- Japan Society for the Promotion of Science
- Kieikai Research Foundation
- Japan Association for Diabetes Education and Care (JADEC)
Zitieren
APA
Rakhat, Y., Wang, L., Han, W., Rustemova, A., Kulzhanova, N., Yamada, Y., Yabe, D., Seino, Y., & Yada, T. (2023). Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice. Nutrients, 15(17), 3765. https://doi.org/10.3390/nu15173765
Vancouver
Rakhat Y, Wang L, Han W, Rustemova A, Kulzhanova N, Yamada Y, et al. Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice. Nutrients. 2023;15(17):3765. doi:10.3390/nu15173765
BibTeX
@article{Rakhat2023,
author = {Rakhat, Yermek and Wang, Lei and Han, Wanxin and Rustemova, Aktolkyn and Kulzhanova, Nazymgul and Yamada, Yuichiro and Yabe, Daisuke and Seino, Yutaka and Yada, Toshihiko},
title = {Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {17},
pages = {3765},
doi = {10.3390/nu15173765}
}
EUVIMED